These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24677790)

  • 1. Renin angiotensin system inhibitors may attenuate low LDL cholesterol-related cancer risk in type 2 diabetes.
    Yang X; Ma RC; So WY; Wang Y; Kong AP; Ozaki R; Xu G; Chan JC
    Diabetes Metab Res Rev; 2014 Jul; 30(5):415-23. PubMed ID: 24677790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effects of low LDL cholesterol with other factors for the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry.
    Yang X; So WY; Ma RC; Kong AP; Lee HM; Xu G; Ozaki R; Chan JC
    Acta Diabetol; 2012 Dec; 49 Suppl 1():S185-93. PubMed ID: 22722949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry.
    Yang X; So WY; Ma RC; Ko GT; Kong AP; Zhao H; Luk AO; Lam CW; Ho CS; Tong PC; Chan JC
    Diabetes Care; 2009 Oct; 32(10):1826-32. PubMed ID: 19592629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-subphenotype interactions for cancer in type 2 diabetes mellitus.
    Yang X; Lee HM; Chan JC
    Nat Rev Endocrinol; 2015 Jun; 11(6):372-9. PubMed ID: 25801918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry.
    Yang X; So WY; Ma RC; Kong AP; Xu G; Chan JC
    Diabetes Metab Res Rev; 2012 Jul; 28(5):379-87. PubMed ID: 22318884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: the Fremantle Diabetes Study.
    Fegan PG; Davis WA; Kamber N; Sivakumar S; Beilby J; Davis TM
    Diabet Med; 2011 Jul; 28(7):849-55. PubMed ID: 21231957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin-angiotensin system inhibitor and statins combination therapeutics - what have we learnt?
    Koh KK; Sakuma I; Hayashi T; Kim SH; Chung WJ
    Expert Opin Pharmacother; 2015 May; 16(7):949-53. PubMed ID: 25747324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cardiovascular events in patients with angiographically documented coronary narrowing with combined renin-angiotensin system inhibitor plus statin versus renin-angiotensin system inhibitor alone versus statin alone (from the Japanese Coronary Artery Disease Study).
    Fujita M; Yamazaki T; Hayashi D; Kohro T; Okada Y; Nagai R;
    Am J Cardiol; 2007 Dec; 100(12):1750-3. PubMed ID: 18082520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy.
    Monson JP; Jönsson P; Koltowska-Häggström M; Kourides I
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):623-8. PubMed ID: 17581260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease.
    Pelusi S; Petta S; Rosso C; Borroni V; Fracanzani AL; Dongiovanni P; Craxi A; Bugianesi E; Fargion S; Valenti L
    PLoS One; 2016; 11(9):e0163069. PubMed ID: 27649410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry).
    Amann U; Kirchberger I; Heier M; Zirngibl A; von Scheidt W; Kuch B; Peters A; Meisinger C
    Am J Cardiol; 2014 Aug; 114(3):329-35. PubMed ID: 24927969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study.
    Edner M; Benson L; Dahlström U; Lund LH
    Eur Heart J; 2015 Sep; 36(34):2318-26. PubMed ID: 26069212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of renin-angiotensin blockers/inhibitors and statins on mortality and functional impairment in polypathological patients.
    Galindo-Ocaña J; Bernabeu-Wittel M; Formiga F; Fuertes-Martín A; Barón-Franco B; Murcia-Zaragoza JM; Moreno-Gaviño L; Ollero-Baturone M;
    Eur J Intern Med; 2012 Mar; 23(2):179-84. PubMed ID: 22284251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renin-angiotensin-system modulators and the incidence of atrial fibrillation following hospitalization for coronary artery disease.
    Singh JP; Kulik A; Levin R; Ellinor PT; Ruskin J; Avorn J; Choudhry NK
    Europace; 2012 Sep; 14(9):1287-93. PubMed ID: 22539600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes.
    Kong AP; Yang X; So WY; Luk A; Ma RC; Ozaki R; Cheung KK; Lee HM; Yu L; Xu G; Chow CC; Chan JC
    BMC Med; 2014 May; 12():76. PubMed ID: 24886453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased circulatory RAS activity can be inhibited by statins in patients with hypercholesterolemia.
    Long H; Wang L; Su H; Xu J; Li J; Peng Q; Dong Y; Cheng X
    J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):126-30. PubMed ID: 23539660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.
    van de Woestijne AP; van der Graaf Y; Liem AH; Cramer MJ; Westerink J; Visseren FL;
    J Am Coll Cardiol; 2013 Nov; 62(20):1834-41. PubMed ID: 23948286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin-angiotensin system blockade in heart failure patients on long-term haemodialysis in Taiwan.
    Tang CH; Chen TH; Wang CC; Hong CY; Huang KC; Sue YM
    Eur J Heart Fail; 2013 Oct; 15(10):1194-202. PubMed ID: 23671265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.